William Parsons

Has grant

Associate Professor

Oberlin College
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

William Parsons is an Assistant Professor at Oberlin College in the United States. His research primarily focuses on protein profiling, enzyme inhibition, and the exploration of hydrolases in therapeutic contexts. Recent publications include studies on activity-based protein profiling, selective inhibitors, and mitochondrial proteases.

Recent Grants

Grant: Close

Activity-based protein profiling of the human rhomboid proteases for inhibitor discovery and enzyme characterization

Open Date: 2022-05-01

Close Date: 2025-04-30

Articles (8)

Hydralazine (HYZ), a treatment for preeclampsia and hypertensive crisis, is listed by the World Health Organization as an essential medicine. Its mode of action has remained unknown through its seven decades of clinical use. Here, we identify 2-aminoethanethiol dioxygenase (ADO), a key mediator of targeted protein degradation, as a selective HYZ target. The drug chelates ADO’s metallocofactor and can alkylate one of its ligands. The resultant inactivation stabilizes regulators of G protein signaling (RGS4 and RGS5) that ADO normally marks for proteolysis, explaining the drug’s vasodilatory activity and comporting with observations of diminished RGS levels in both clinical preeclampsia and a mouse model thereof. Its inhibition of ADO suggested use of HYZ against glioblastoma (GBM); indeed, a single dose robustly senesces cultured GBM cells. By establishing ADO as a nexus for GBM and preeclampsia and connecting it to HYZ, the results create opportunities for directed tailoring of the old drug for new therapies.

Year:

2025

Activity-based protein profiling (ABPP) technology has served as a powerful platform for studying proteins for more than two decades. However, the further growth of this field depends on the development of new probe structures to expand the proportion of the proteome that can be studied using these methods. Inspired by previous reports of succinimide-containing covalent inhibitors for proteases, we synthesized a panel of potential probe structures with a succinimide reactive group and a terminal alkyne tag suitable for subsequent azide-alkyne click chemistry. Members of this panel with an N-arylsulfonyl linker produce labeling of both purified serine proteases as well as proteins in complex cellular lysates. We found that one of these probes labels the human rhomboid protease RHBDL2 at low micromolar concentrations and can be competed with active-site inhibitors. Our studies establish succinimide as a new reactive group for the development of activity-based probes and offer a new chemical tool for studying a class of enzymes with limited functional characterization.

Year:

2025

Year:

2024

The vasodilator hydralazine (HYZ) has been used clinically for ∼ 70 years and remains on the World Health Organization’s List of Essential Medicines as a therapy for preeclampsia. Despite its longstanding use and the concomitant progress toward a general understanding of vasodilation, the target and mechanism of HYZ have remained unknown. We show that HYZ selectively targets 2-aminoethanethiol dioxygenase (ADO) by chelating its metal cofactor and alkylating one of its ligands. This covalent inactivation slows entry of proteins into the Cys/N-degron pathway that ADO initiates. HYZ’s capacity to stabilize regulators of G-protein signaling (RGS4/5) normally marked for degradation by ADO explains its effect on blood vessel tension and comports with prior associations of insufficient RGS levels with human preeclampsia and analogous symptoms in mice. The established importance of ADO in glioblastoma led us to test HYZ in these cell types. Indeed, a single treatment induced senescence, suggesting a potential new HYZ-based therapy for this deadly brain cancer.

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Megan L. Matthews

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Jiasong (Jason) Li

Assistant Professor of Research

University of Texas at San Antonio

UNITED STATES
View details

Aimin Liu

Johnson Foundation Professor of Chemical Enzymology

University of Texas at San Antonio

UNITED STATES
View details

Zongtao Lin

Assistant Professor

Rutgers University

UNITED STATES
View details

J. Martin Bollinger

Marker Professor of Natural Products Chemistry

Pennsylvania State University

UNITED STATES
View details

Kirill A. Martemyanov

Professor and Chair

University of Miami

UNITED STATES
View details